Shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) rose 4.9% during trading on Wednesday . The company traded as high as $11.56 and last traded at $11.56, with a volume of 124,460 shares traded. The stock had previously closed at $11.02.

SCMP has been the topic of a number of recent analyst reports. Roth Capital reiterated a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Tuesday, July 12th. Mizuho reiterated a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Monday, July 11th. Maxim Group restated a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Monday, July 11th. WallachBeth Capital upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Thursday, May 5th. Finally, Guggenheim restated a “buy” rating and issued a $29.00 target price on shares of Sucampo Pharmaceuticals in a research note on Wednesday, May 4th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Sucampo Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $21.00.

The company has a market cap of $494.51 million and a P/E ratio of 22.97. The stock’s 50 day moving average price is $11.25 and its 200-day moving average price is $11.84.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.02. During the same period last year, the company earned $0.14 EPS. The firm earned $47.20 million during the quarter, compared to analysts’ expectations of $44.11 million. The business’s quarterly revenue was up 60.0% on a year-over-year basis. Equities research analysts anticipate that Sucampo Pharmaceuticals Inc. will post $1.02 earnings per share for the current year.

Other institutional investors recently bought and sold shares of the company. Globeflex Capital L P boosted its position in Sucampo Pharmaceuticals by 76.5% in the fourth quarter. Globeflex Capital L P now owns 65,588 shares of the biopharmaceutical company’s stock worth $1,134,000 after buying an additional 28,431 shares during the last quarter. Shell Asset Management Co. bought a new position in Sucampo Pharmaceuticals during the fourth quarter worth $1,324,000. Systematic Financial Management LP boosted its position in Sucampo Pharmaceuticals by 18.1% in the fourth quarter. Systematic Financial Management LP now owns 101,745 shares of the biopharmaceutical company’s stock worth $1,759,000 after buying an additional 15,590 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its position in Sucampo Pharmaceuticals by 8.5% in the fourth quarter. GSA Capital Partners LLP now owns 219,881 shares of the biopharmaceutical company’s stock worth $3,802,000 after buying an additional 17,172 shares during the last quarter.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.